Glucovance and Tradjenta drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Glucovance (glyburide; metformin hydrochloride) and Tradjenta (linagliptin). Common drug interactions include renal failure among females and chronic kidney disease among males.

The phase IV clinical study analyzes what interactions people have when they take Glucovance and Tradjenta. It is created by eHealthMe based on reports of 31 people who take the same drugs from the FDA, and is updated regularly.

What is Glucovance?

Glucovance has active ingredients of glyburide; metformin hydrochloride. It is often used in diabetes. eHealthMe is studying from 6,302 Glucovance users. Check the latest studies of Glucovance.

What is Tradjenta?

Tradjenta has active ingredients of linagliptin. It is often used in diabetes. eHealthMe is studying from 9,987 Tradjenta users. Check the latest studies of Tradjenta.



On Aug, 01, 2026

31 people who take Glucovance and Tradjenta together, and have interactions are studied.

Glucovance and Tradjenta drug interactions.

What are the common drug interactions of Glucovance and Tradjenta, by gender? *:

female:

  1. Renal failure (kidney dysfunction)
  2. Renal injury (kidney injury)
  3. Breast cancer
  4. Ejection fraction decreased (systolic heart failure)
  5. Feeling hot
  6. Hyperparathyroidism secondary (an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium-secondary)
  7. Nephrogenic anaemia (anaemia due to kidney disease)
  8. Nephropathy (damage to or disease of a kidney)
  9. Oropharyngeal pain
  10. Blood glucose decreased

male:

  1. Chronic kidney disease
  2. Drug ineffective
  3. Pancreatitis (inflammation of pancreas)
  4. Swollen tongue (swelling of tongue)
  5. Death
  6. Hyperparathyroidism secondary (an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium-secondary)
  7. Myocardial infarction (destruction of heart tissue resulting from obstruction of the blood supply to the heart muscle)
  8. Nephrogenic anaemia (anaemia due to kidney disease)
  9. Renal failure (kidney dysfunction)

What are the common drug interactions of Glucovance and Tradjenta, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

  1. Cardiac arrest
  2. Dysgeusia (disorder of the sense of taste)
  3. Ear discomfort
  4. Eye discharge
  5. Eye pruritus (eye itching)
  6. Feeling hot
  7. Hunger
  8. Hyperhidrosis (abnormally increased sweating)
  9. Migraine (headache)
  10. Nausea (feeling of having an urge to vomit)

30-39:

n/a

40-49:

n/a

50-59:

  1. Chronic kidney disease
  2. Renal failure (kidney dysfunction)
  3. Feeling hot
  4. Hyperparathyroidism secondary (an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium-secondary)
  5. Nephrogenic anaemia (anaemia due to kidney disease)
  6. Oropharyngeal pain
  7. Peripheral swelling
  8. Purpura (purplish discoloration of the skin)
  9. Rhinorrhoea (watery mucus discharge from the nose)
  10. Skin disorder (skin disease)

60+:

  1. Chronic kidney disease
  2. Drug ineffective
  3. Death
  4. Dizziness
  5. Hypoglycaemia (deficiency of glucose in the bloodstream)
  6. Intraductal papillary mucinous neoplasm (tumour (neoplasm) that grows within the pancreatic ducts)
  7. Myocardial infarction (destruction of heart tissue resulting from obstruction of the blood supply to the heart muscle)
  8. Pancreatitis (inflammation of pancreas)
  9. Renal injury (kidney injury)
  10. Hyperparathyroidism secondary (an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium-secondary)

What are the existing conditions these people have? *

  1. High Blood Cholesterol: 12 people, 38.71%
  2. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 12 people, 38.71%
  3. Type 2 Diabetes: 11 people, 35.48%
  4. High Blood Pressure: 11 people, 35.48%
  5. Pain: 9 people, 29.03%
  6. Stress And Anxiety: 8 people, 25.81%
  7. Rashes (redness): 7 people, 22.58%
  8. Gastric Ulcer (stomach ulcer): 7 people, 22.58%
  9. Blood Magnesium Decreased: 7 people, 22.58%
  10. Blood Iron Decreased: 7 people, 22.58%

* Approximation only. Some reports may have incomplete information.

Do you take Glucovance and Tradjenta?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Glucovance and Tradjenta:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Glucovance:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Tradjenta:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Glucovance and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Tradjenta and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on glyburide; metformin hydrochloride and linagliptin (the active ingredients of Glucovance and Tradjenta, respectively), and Glucovance and Tradjenta (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: